Nicotine Pouch Industry News: September 2026 Roundup

September 2026 has been one of the most active months in nicotine pouch regulatory and brand history. The FDA expanded its ZYN authorization to an entirely new product line, its pilot program produced its first batch of additional brand authorizations, and the agency signalled even further acceleration is incoming. On the brand side, ALP — the US challenger backed by Tucker Carlson and fronted by Conor McGregor — completed its European push by landing a headline boxing partnership. Here's everything that mattered this month.

ZYN ULTRA: What the New FDA Authorization Means

On August 21, 2026, the FDA authorized 11 ZYN ULTRA nicotine pouch products made by Swedish Match USA, Inc. through the standard premarket tobacco product application (PMTA) pathway. This is distinct from the landmark Modified Risk Tobacco Product (MRTP) authorization ZYN received on June 30, 2026 — which allowed ZYN to make explicit risk-reduction claims. The ULTRA authorization is a separate product line expansion, suggesting Swedish Match is broadening the ZYN portfolio beyond its existing range.

The ZYN ULTRA designation points toward higher-strength or enhanced-format products — the term "ULTRA" in the nicotine category consistently tracks to higher mg-per-pouch formulations. No full product details were immediately disclosed in the FDA's authorization announcement, but with 11 products across what is likely a range of flavours and strengths, the expansion looks directionally similar to the 20-product MRTP batch from June. It positions ZYN to better compete in the strong-nicotine segment where European brands like ZEUS, KUMA, and extra-strong European pouches have historically dominated.

This also signals that the FDA's appetite for ZYN expansion is still growing — just 3 months after granting the most significant nicotine product authorization in US regulatory history, the agency is adding 11 more products to the approved roster. The FDA's Center for Tobacco Products had reduced its PMTA application backlog by approximately 70% in 2025, and the ULTRA authorization demonstrates that momentum has continued into 2026.

The FDA Pilot Program Is Producing Results

On August 4, 2026, the FDA's PMTA pilot fast-track program produced its first batch of authorized products outside the ZYN ecosystem. Four new nicotine pouches were cleared for marketing: Rich Berry 2mg, Cappuccino 2mg, Cappuccino 4mg, and Autumn Spice 2mg. The manufacturer was not prominently identified in initial reports, but the flavour profile — particularly the coffee/caramel and spiced fruit combinations — is consistent with the Nordic Spirit portfolio owned by Japan Tobacco International.

The significance here isn't just the four products. It's that the FDA's pilot program — which was specifically designed to accelerate PMTA processing times — is now delivering authorizations for brands other than ZYN. This opens the door for VELO (British American Tobacco) and potentially LOOP, ZEUS, and XQS to pursue US market entry through an expedited pathway. The US nicotine pouch market, currently dominated by ZYN at roughly 65% market share, becomes far more interesting competitively if European brands can clear the FDA faster.

FDA Set to Announce Even Further Acceleration

In news published September 23, 2026, Reuters reported that the FDA is expected to announce additional measures in the coming days to speed up approvals for both vaping products and nicotine pouches. The report, citing sources familiar with the matter, follows several months of the FDA CTP signalling a more innovation-friendly regulatory posture — including the ZYN MRTP in June, the ULTRA authorization in August, and the pilot program results in August.

The broader context matters: the current US administration has taken a pro-harm-reduction stance on nicotine products, and the FDA CTP's Acting Director has explicitly stated that efficient evaluation of applications is a priority. A further acceleration announcement would likely include structural changes to how PMTA applications are reviewed — potentially shorter review windows, clearer documentation requirements, or expanded pilot program criteria. For European manufacturers with pending US applications, this is the news they've been waiting for.

Compare this with the EU's position: European pouches remain freely available but TPD3 — the revision to the Tobacco Products Directive — is still working toward a December 2026 legislative proposal, with 41,694 consultation responses and 12 member states pushing flavour bans. The regulatory trajectory in the US and the EU is moving in opposite directions.

ALP Signs Matchroom Boxing — Europe's Biggest Nicotine Pouch Marketing Move

On September 4, 2026, Turning Point Brands' ALP brand was named the Official Nicotine Pouch Partner of Matchroom Boxing, with category exclusivity across three major UK and Ireland boxing events beginning at Croke Park, Dublin on September 5. Matchroom Boxing — the promotion run by Eddie Hearn, responsible for Anthony Joshua, Katie Taylor, and the UK's biggest professional fight cards — is one of the highest-reach boxing promoters in the world. The deal gives ALP ringside visibility in front of audiences of hundreds of thousands at venue and millions on DAZN and Sky Sports.

The timing is strategic. ALP completed its Phase 1 European launch on July 23, 2026 — entering the UK, Ireland, Greece, Switzerland, and Romania simultaneously, with Conor McGregor as its global brand partner. McGregor's combination of global brand recognition, Irish identity, and combat sports association makes him a natural face for a boxing-adjacent nicotine pouch campaign. The Croke Park event was effectively the ALP brand's public European debut at scale.

ALP's positioning is challenger-brand aggressive: the campaign language targets smokers and snus users specifically, with messaging around switching rather than nicotine reduction. The brand's existing US marketing — Tucker Carlson, American cultural identity, "freedom" framing — is being substantially adapted for European markets, where the boxing and sport-lifestyle angle is the primary vehicle. ALP has signalled a Phase 2 expansion to Czech Republic, Poland, Portugal, Spain, Sweden, and Denmark later in 2026.

Industry Impact: What This Means for European Consumers

Development	Market Impact	Timeframe
ZYN ULTRA FDA authorized (11 products)	ZYN expands into higher-strength segment in the US; signals further US volume growth	August 21, 2026
PMTA pilot program: 4 new brands authorized	Non-ZYN brands (potentially Nordic Spirit/JTI) gain US market access; EU brands can now pursue expedited US entry	August 4, 2026
FDA further acceleration expected	Faster route for VELO, LOOP, XQS to enter or expand in the US	Announcement imminent
ALP Matchroom Boxing partnership	New competitive challenger in UK/Ireland; increases consumer awareness, could drive category growth	September 5, 2026
EU TPD3 consultation closed (Aug 14)	Potential flavour restrictions December 2026 proposal; regulatory uncertainty for EU brands	December 2026 target

For everyday consumers in Europe, the immediate takeaway is that product choice is expanding, competitive pricing is likely to follow as more brands compete for attention, and the underlying regulatory environment in the EU — while being closely watched — has not yet changed. The full range of ZYN, VELO, LOOP, XQS, ZEUS, KUMA, and C.R.E.A.M remains freely available, competitively priced, and shippable across the EU.

FAQ: September 2026 Industry News

What is ZYN ULTRA and how is it different from regular ZYN?

ZYN ULTRA is a new product line within the ZYN brand, authorized by the FDA on August 21, 2026 via the PMTA pathway. It is separate from the 20 products that received Modified Risk Tobacco Product authorization in June 2026. The "ULTRA" designation typically signals higher nicotine strength or an enhanced format. Full product details including specific flavours and mg levels have not yet been disclosed by Swedish Match USA.

Does the FDA's faster approval process affect European nicotine pouch users?

Not directly — the FDA governs US products. But it matters for European brands: if VELO, LOOP, XQS, or ZEUS can now gain US market authorization faster, their US volumes grow, which historically increases R&D investment and product innovation that then flows back to European markets through new flavours and format improvements.

Is ALP available to buy in Europe now?

Yes — ALP launched in Phase 1 European markets (UK, Ireland, Greece, Switzerland, Romania) in July 2026. Phase 2 (Czech Republic, Poland, Portugal, Spain, Sweden, Denmark) is planned for later in 2026. At present, the established brands — ZYN, VELO, LOOP, ZEUS, XQS, and KUMA — cover a wider range of European markets and strength profiles than ALP's current EU offering.

Should I be worried about the EU TPD3 flavour ban proposals?

The TPD3 legislative proposal is expected in December 2026. As of the consultation close in August 2026, no ban text has been published and no specific nicotine limits have been proposed. Twelve member states are pushing for flavour restrictions, but the legislative process typically takes 12–24 months after proposal before any regulation takes effect. There is no immediate change to product availability.

Final Thoughts

September 2026 has been the most consequential month for the global nicotine pouch industry since ZYN's MRTP authorization in June. Regulatory acceleration in the US and aggressive brand-building in Europe are reshaping the competitive landscape. The brands available at The Snus Outlet — established, authorized, and freely shipping across the EU — are right at the centre of this shift.

Shop the full range at The Snus Outlet — ZYN, VELO, LOOP, ZEUS, XQS, KUMA, and C.R.E.A.M, with free EU shipping on orders over €99.